Li Jun, Kato Masato, Chuang David T
Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9038, USA.
J Biol Chem. 2009 Dec 4;284(49):34458-67. doi: 10.1074/jbc.M109.065557. Epub 2009 Oct 15.
The mitochondrial pyruvate dehydrogenase complex (PDC) is down-regulated by phosphorylation catalyzed by pyruvate dehydrogenase kinase (PDK) isoforms 1-4. Overexpression of PDK isoforms and therefore reduced PDC activity prevails in cancer and diabetes. In the present study, we investigated the role of the invariant C-terminal DW-motif in inhibition of human PDK2 by dichloroacetate (DCA). Substitutions were made in the DW-motif (Asp-382 and Trp-383) and its interacting residues (Tyr-145 and Arg-149) in the other subunit of PDK2 homodimer. Single and double mutants show 20-60% residual activities that are not stimulated by the PDC core. The R149A and Y145F/R149A mutants show drastic increases in apparent IC(50) values for DCA, whereas binding affinities for DCA are comparable with wild-type PDK2. Both R149A and Y145F variants exhibit increased similar affinities for ADP and ATP, mimicking the effects of DCA. The R149A and the DW-motif mutations (D382A/W383A) forestall binding of the lipoyl domain of PDC to these mutants, analogous to wild-type PDK2 in the presence of DCA and ADP. In contrast, the binding of a dihydrolipoamide mimetic AZD7545 is largely unaffected in these PDK2 variants. Our results illuminate the pivotal role of the DW-motif in mediating communications between the DCA-, the nucleotide-, and the lipoyl domain-binding sites. This signaling network locks PDK2 in the inactive closed conformation, which is in equilibrium with the active open conformation without DCA and ADP. These results implicate the DW-motif anchoring site as a drug target for the inhibition of aberrant PDK activity in cancer and diabetes.
线粒体丙酮酸脱氢酶复合体(PDC)受丙酮酸脱氢酶激酶(PDK)亚型1 - 4催化的磷酸化作用而被下调。在癌症和糖尿病中,PDK亚型的过表达以及由此导致的PDC活性降低较为普遍。在本研究中,我们探究了不变的C末端DW基序在二氯乙酸(DCA)抑制人PDK2中的作用。在PDK2同二聚体另一亚基的DW基序(Asp - 382和Trp - 383)及其相互作用残基(Tyr - 145和Arg - 149)上进行了替换。单突变体和双突变体显示出20% - 60%的残余活性,且不受PDC核心的刺激。R149A以及Y145F/R149A突变体对DCA的表观IC(50)值大幅增加,而对DCA的结合亲和力与野生型PDK2相当。R149A和Y145F变体对ADP和ATP的亲和力均增加,类似于DCA的作用。R149A和DW基序突变(D382A/W383A)阻止了PDC的硫辛酰结构域与这些突变体的结合,类似于在存在DCA和ADP时的野生型PDK2。相反,二氢硫辛酰胺模拟物AZD7545的结合在这些PDK2变体中基本不受影响。我们的结果阐明了DW基序在介导DCA、核苷酸和硫辛酰结构域结合位点之间通讯中的关键作用。这个信号网络将PDK2锁定在无活性的闭合构象中,该构象与没有DCA和ADP时的活性开放构象处于平衡状态。这些结果表明DW基序锚定位点是抑制癌症和糖尿病中异常PDK活性的药物靶点。